US Pharma MarketingLandmark approval for pancreatic cancer; Reactions to Lilly’s Phase 1 secrecy; and more
Welcome back to Endpoints Weekly! The big news this week was the FDA’s approval of Revolution Medicines’ pancreatic cancer treatment Rasonque. The drug stunned researchers and spurred excitement in April ... Topic Hubs AI drug discovery: News, analysis and interviews Antibody-drug conjugates: The next wave of targeted cancer drugs Biopharma M&A and dealmaking: Who’s buying and why Biopharma people moves: CEO changes, executive hires, board positions Biotech IPOs: Tracking the market for new public offerings Biotech venture funding: Who’s raising and where the money is going Cell and gene therapy manufacturing: Scaling the next frontier China biotech: Licensing deals and…
Welcome back to Endpoints Weekly! The big news this week was the FDA’s approval of Revolution Medicines’ pancreatic cancer treatment Rasonque. The drug stunned researchers and spurred excitement in April, when it nearly doubled patients’ ...
Source: Endpoints News